TolerogenixX Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
4
TolerogenixX General Information
Description
Developer of a patented and clinically tested cell therapy technique created for individualized immunosuppression in transplant patients. The company's cell therapy technique helps in the targeted disabling of undesired reactions caused by the immune system's defenses, enabling patients who received transplants to become tolerant of the donated organ.
Contact Information
Website
www.tolerogenixx.comCorporate Office
- Im Neuenheimer Feld 162
- 69120 Heidelberg
- Germany
Corporate Office
- Im Neuenheimer Feld 162
- 69120 Heidelberg
- Germany
TolerogenixX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 5. Later Stage VC (Series A) | 06-Jul-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 22-Nov-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC | Cancelled | Generating Revenue | ||||
| 2. Seed Round | 01-Jun-2017 | Completed | Generating Revenue | |||
| 1. Grant | 14-Jul-2015 | $27.9K | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TolerogenixX Comparisons
Industry
Financing
Details
TolerogenixX Competitors (3)
One of TolerogenixX’s 3 competitors is Maxion Therapeutics, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Maxion Therapeutics | Venture Capital-Backed | London, United Kingdom | ||||
| SciRhom | Venture Capital-Backed | Martinsried, Germany | ||||
| Quell Therapeutics | Venture Capital-Backed | London, United Kingdom |
TolerogenixX Patents
TolerogenixX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019447492-A1 | Mic therapy for specific immunosuppression in transplantation | Active | 17-May-2019 | ||
| AU-2019447492-B2 | Mic therapy for specific immunosuppression in transplantation | Active | 17-May-2019 | ||
| CA-3139853-A1 | Mic therapy for specific immunosuppression in transplantation | Pending | 17-May-2019 | ||
| EP-3784253-A1 | Mic therapy for specific immunosuppression in transplantation | Active | 17-May-2019 | ||
| EP-3784253-B1 | Mic therapy for specific immunosuppression in transplantation | Active | 17-May-2019 | A61P37/06 |
TolerogenixX Signals
TolerogenixX Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kalodion | Family Office | Minority | ||
| Bundesministerium für Wirtschaft und Klimaschutz | Government | Minority | ||
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| Science4Life | Accelerator/Incubator |
TolerogenixX FAQs
-
When was TolerogenixX founded?
TolerogenixX was founded in 2006.
-
Where is TolerogenixX headquartered?
TolerogenixX is headquartered in Heidelberg, Germany.
-
What is the size of TolerogenixX?
TolerogenixX has 4 total employees.
-
What industry is TolerogenixX in?
TolerogenixX’s primary industry is Drug Discovery.
-
Is TolerogenixX a private or public company?
TolerogenixX is a Private company.
-
What is TolerogenixX’s current revenue?
The current revenue for TolerogenixX is .
-
How much funding has TolerogenixX raised over time?
TolerogenixX has raised $12.6M.
-
Who are TolerogenixX’s investors?
Kalodion, Bundesministerium für Wirtschaft und Klimaschutz, High-Tech Gründerfonds, and Science4Life have invested in TolerogenixX.
-
Who are TolerogenixX’s competitors?
Maxion Therapeutics, SciRhom, and Quell Therapeutics are competitors of TolerogenixX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process